두경부암의 방사선 저항성 기전 및 극복방안 연구 = The Mechanisms and Overcoming Strategies of the Radioresistance in Head and Neck Cancer

다국어 초록 (Multilingual Abstract)

Radiotherapy plays an important role in the treatment of most of solid tumors including headand neck squamous cell carcinoma (HNSCC). Radioresistance can lead to locoregional recur-rence and distant metastases. Despite significant progress in research of radioresistance, itsprediction and overcoming strategies remain challenging. This review describes the potentialbiomarkers correlated to the radioresistance and complex signal pathway in mechanism of ra-dioresistance focusing on the PI3K and EphA3 pathway.

참고문헌 (Reference)

1 Qin CJ, "XRCC2as a predictive biomarker for radioresistance in locally advanced rectal cancer patients undergoing preoperative radiotherapy" 6 (6): 32193-32204, 2015

2 Lee WH, "Tristetraprolin regulates phagocytosis through interaction with CD47 in head and neck cancer" 24 (24): 541-, 2022

3 Papa A, "The PTEN–PI3K axis in cancer" 9 (9): 153-, 2019

4 Mardanshahi A, "The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines" 48 (48): 1-14, 2021

5 Goldstein M, "The DNA damage response : Implications for tumor responses to radiation and chemotherapy" 66 : 129-143, 2015

6 Simpson DR, "Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck" 51 (51): 291-298, 2015

7 Vilaplana-Lopera N, "Targeting hypoxia : Revival of old remedies" 11 (11): 1604-, 2021

8 Vail ME, "Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment" 74 (74): 4470-4481, 2014

9 Lodola A, "Targeting Eph/ephrin system in cancer therapy" 142 : 152-162, 2017

10 Horn D, "Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma" 19 (19): 795-805, 2015

11 Stakheyeva M, "Role of the immune component of tumor microenvironment in the efficiency of cancer treatment : Perspectives for the personalized therapy" 23 (23): 4807-4826, 2017

12 Jiang N, "Role of PI3K/AKT pathway in cancer : The framework of malignant behavior" 47 (47): 4587-4629, 2020

13 Bhattacharya P, "Receptor tyrosine kinase signaling in cancer radiotherapy and its targeting for tumor radiosensitization" 94 (94): 628-644, 2018

14 Larionova I, "Radiotherapy resistance : Identifying universal biomarkers for various human cancers" 148 (148): 1015-1031, 2022

15 Nam HY, "Radioresistant cancer cells can be conditioned to enter senescence by mTOR inhibition" 73 (73): 4267-4277, 2013

16 Perri F, "Radioresistance in head and neck squamous cell carcinoma : Biological bases and therapeutic implications" 37 (37): 763-770, 2015

17 Kaidar-Person O, "Precision medicine in head and neck cancer" 40 : 13-16, 2018

18 Han MW, "Phosphorylation of PI3K regulatory subunit p85 contributes to resistance against PI3K inhibitors in radioresistant head and neck cancer" 78 : 56-63, 2018

19 Leslie NR, "PTEN function : How normal cells control it and tumour cells lose it" 382 (382): 1-11, 2004

20 Worby CA, "PTEN" 83 : 641-669, 2014

21 Marquard FE, "PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer" 172 : 113729-, 2020

22 Massacesi C, "PI3K inhibitors as new cancer therapeutics : Implications for clinical trial design" 9 : 203-210, 2016

23 Madsen RR, "PI3K in stemness regulation : From development to cancer" 48 (48): 301-315, 2020

24 Hill RM, "Overcoming the impact of hypoxia in driving radiotherapy resistance in head and neck squamous cell carcinoma" 14 (14): 4130-, 2022

25 Jackson RK, "Overcoming radioresistance: small molecule radiosensitisers and hypoxia-activated prodrugs" 31 (31): 290-302, 2019

26 Yamamoto VN, "Overcoming radioresistance in head and neck squamous cell carcinoma" 63 : 44-51, 2016

27 Burris HA 3rd, "Overcoming acquired resistance to anticancer therapy : Focus on the PI3K/AKT/mTOR pathway" 71 (71): 829-842, 2013

28 Boutilier AJ, "Macrophage polarization states in the tumor microenvironment" 22 (22): 6995-, 2021

29 Swords RT, "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" 50 : 123-131, 2016

30 Larionova I, "Interaction of tumor-associated macrophages and cancer chemotherapy" 8 (8): 1596004-, 2019

31 Rankin EB, "Hypoxic control of metastasis" 352 (352): 175-180, 2016

32 Moreno Roig E, "HIF-1α and HIF-2α differently regulate the radiation sensitivity of NSCLC cells" 8 (8): 45-, 2019

33 Chang HW, "Expression of Ku80 correlates with sensitivities to radiation in cancer cell lines of the head and neck" 42 (42): 979-986, 2006

34 La Rocca F, "EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells" 40 (40): 483-496, 2017

35 Day BW, "EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme" 23 (23): 238-248, 2013

36 Kim SH, "EphA3 maintains radioresistance in head and neck cancers through epithelial mesenchymal transition" 47 : 122-130, 2018

37 Janes PW, "EphA3 biology and cancer" 32 (32): 176-189, 2014

38 Charmsaz S, "EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia" 31 (31): 1779-1787, 2017

39 Day BW, "Eph receptors as therapeutic targets in glioblastoma" 111 (111): 1255-1261, 2014

40 Xi HQ, "Eph receptors and ephrins as targets for cancer therapy" 16 (16): 2894-2909, 2012

41 Brantley-Sieders D, "Eph receptor tyrosine kinases in tumor and tumor microenvironment" 10 (10): 3431-3442, 2004

42 Héroult M, "Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression" 312 (312): 642-650, 2006

43 Kim SH, "EPHA3contributes to epigenetic suppression of PTEN in radioresistant head and neck cancer" 11 (11): 599-, 2021

44 Keane N, "EPHA3 as a novel therapeutic target in the hematological malignancies" 5 (5): 325-340, 2012

45 Biffi G, "Diversity and biology of cancer-associated fibroblasts" 101 (101): 147-176, 2021

46 Chen Y, "Clinical and therapeutic relevance of cancer-associated fibroblasts" 18 (18): 792-804, 2021

47 de Jong MC, "CD44 expression predicts local recurrence after radiotherapy in larynx cancer" 16 (16): 5329-5338, 2010

48 Huo X, "Analysis of the expression level and methylation of tumor protein p53, phosphatase and tensin homolog and mutS homolog 2 in N-methyl-N-nitrosoureainduced thymic lymphoma in C57BL/6 mice" 14 (14): 4339-4348, 2017

49 Xi HQ, "Aberrant expression of EphA3 in gastric carcinoma : Correlation with tumor angiogenesis and survival" 47 (47): 785-794, 2012